WO2000015178A3 - Computer implemented pharmacokinetics method and program - Google Patents

Computer implemented pharmacokinetics method and program Download PDF

Info

Publication number
WO2000015178A3
WO2000015178A3 PCT/US1999/021001 US9921001W WO0015178A3 WO 2000015178 A3 WO2000015178 A3 WO 2000015178A3 US 9921001 W US9921001 W US 9921001W WO 0015178 A3 WO0015178 A3 WO 0015178A3
Authority
WO
WIPO (PCT)
Prior art keywords
tool
methods
computer
predicting
interest
Prior art date
Application number
PCT/US1999/021001
Other languages
French (fr)
Other versions
WO2000015178A2 (en
WO2000015178A9 (en
Inventor
George M Grass
Glen D Leesman
Daniel A Norris
Patrick J Sinko
John E Wehrli
Original Assignee
Navicyte Inc
George M Grass
Glen D Leesman
Daniel A Norris
Patrick J Sinko
John E Wehrli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navicyte Inc, George M Grass, Glen D Leesman, Daniel A Norris, Patrick J Sinko, John E Wehrli filed Critical Navicyte Inc
Priority to AU62474/99A priority Critical patent/AU768368B2/en
Priority to JP2000569763A priority patent/JP2002524809A/en
Priority to EP99949642A priority patent/EP1144675A4/en
Priority to CA002344036A priority patent/CA2344036A1/en
Publication of WO2000015178A2 publication Critical patent/WO2000015178A2/en
Publication of WO2000015178A3 publication Critical patent/WO2000015178A3/en
Publication of WO2000015178A9 publication Critical patent/WO2000015178A9/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/62—Design of libraries
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The present invention relates to a pharmacokinetic-based design and selection tool (PK tool) and methods for predicting absoption of an administered compound of interest. The methods utilize the tools, and optionally a separately operable component or subsystem thereof. The PK tool includes as computer-readable components: (1) input/output system; (2) physiologic-based simulation model of one or more segments of a mammalian system of interest having one or more physiological barriers to absorption that is based on the selected route of administration; and (3) simulation engine having a differential equation solver. The invention also provides methods for optimizing as well as enabling minimal input requirements a physiologic-based simulation model for predicting in vivo absorption, and optionally one or more additional properties, from either in vitro or in vivo data. The PK tool of the invention may be provided as a computer system, as an article of manufacture in the form of a computer-readable medium, or a computer program product and the like. Subsystems and individual components of the PK tool also can be utilized and adapted in a variety of disparate applications for predicting the fate of an administered compound. The PK tool and methods of the invention can be used to screen and design compound libraries, select and design drugs, as well as predict drug efficacy in mammals from in vitro and/or in vivo data of one or more compounds of interest. The PK tool and methods of the invention also find use in selecting, designing, and preparing drug compounds, and multi-compound drugs and drug formulations (i.e., drug delivery system) for preparation of medicaments for use in treating mammalian disorders.
PCT/US1999/021001 1998-09-14 1999-09-14 Computer implemented pharmacokinetics method and program WO2000015178A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU62474/99A AU768368B2 (en) 1998-09-14 1999-09-14 Pharmacokinetic-based drug design tool and method
JP2000569763A JP2002524809A (en) 1998-09-14 1999-09-14 Pharmacokinetic-based drug design tools and methods
EP99949642A EP1144675A4 (en) 1998-09-14 1999-09-14 Pharmacokinetic-based drug design tool and method
CA002344036A CA2344036A1 (en) 1998-09-14 1999-09-14 Pharmacokinetic-based drug design tool and method

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US10029098P 1998-09-14 1998-09-14
US10022498P 1998-09-14 1998-09-14
US60/100,224 1998-09-14
US60/100,290 1998-09-14
US10923298P 1998-11-18 1998-11-18
US10923498P 1998-11-18 1998-11-18
US60/109,234 1998-11-18
US60/109,232 1998-11-18
US32006999A 1999-05-26 1999-05-26
US09/320,270 US20020035459A1 (en) 1998-09-14 1999-05-26 Pharmacokinetic-based drug design tool and method
US09/320,545 US6542858B1 (en) 1998-09-14 1999-05-26 Pharmacokinetic-based drug design tool and method
US09/320,371 1999-05-26
US09/320,372 1999-05-26
US09/320,544 US20020010550A1 (en) 1998-09-14 1999-05-26 Pharmacokinetic-based drug design tool and method
US09/320,544 1999-05-26
US09/320,545 1999-05-26
US09/320,270 1999-05-26
US09/320,372 US20010041964A1 (en) 1998-09-14 1999-05-26 Pharmacokinetic-based drug design tool and method
US09/320,069 1999-05-26
US09/320,371 US6647358B2 (en) 1998-09-14 1999-05-26 Pharmacokinetic-based drug design tool and method

Publications (3)

Publication Number Publication Date
WO2000015178A2 WO2000015178A2 (en) 2000-03-23
WO2000015178A3 true WO2000015178A3 (en) 2001-07-26
WO2000015178A9 WO2000015178A9 (en) 2001-10-04

Family

ID=27536966

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/021001 WO2000015178A2 (en) 1998-09-14 1999-09-14 Computer implemented pharmacokinetics method and program
PCT/US1999/021151 WO2000016231A1 (en) 1998-09-14 1999-09-14 Method for screening and producing compound libraries

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1999/021151 WO2000016231A1 (en) 1998-09-14 1999-09-14 Method for screening and producing compound libraries

Country Status (8)

Country Link
US (6) US20020010550A1 (en)
EP (2) EP1185948B1 (en)
JP (2) JP2003521673A (en)
AT (1) ATE319136T1 (en)
AU (2) AU768368B2 (en)
CA (2) CA2343914A1 (en)
DE (1) DE69930137D1 (en)
WO (2) WO2000015178A2 (en)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1010487A6 (en) * 1996-06-11 1998-10-06 Unilin Beheer Bv FLOOR COATING CONSISTING OF HARD FLOOR PANELS AND METHOD FOR MANUFACTURING SUCH FLOOR PANELS.
US20040117125A1 (en) * 1999-04-26 2004-06-17 Hao Chen Drug discovery method and apparatus
US7759113B2 (en) 1999-04-30 2010-07-20 The General Hospital Corporation Fabrication of tissue lamina using microfabricated two-dimensional molds
US20050089923A9 (en) * 2000-01-07 2005-04-28 Levinson Douglas A. Method and system for planning, performing, and assessing high-throughput screening of multicomponent chemical compositions and solid forms of compounds
US20070020662A1 (en) * 2000-01-07 2007-01-25 Transform Pharmaceuticals, Inc. Computerized control of high-throughput experimental processing and digital analysis of comparative samples for a compound of interest
US20070021929A1 (en) * 2000-01-07 2007-01-25 Transform Pharmaceuticals, Inc. Computing methods for control of high-throughput experimental processing, digital analysis, and re-arraying comparative samples in computer-designed arrays
US7216113B1 (en) * 2000-03-24 2007-05-08 Symyx Technologies, Inc. Remote Execution of Materials Library Designs
US7776021B2 (en) * 2000-04-28 2010-08-17 The Charles Stark Draper Laboratory Micromachined bilayer unit for filtration of small molecules
US6549803B1 (en) * 2000-05-08 2003-04-15 Image-Guided Neurologics Inc. Method and apparatus for targeting material delivery to tissue
WO2002010746A2 (en) * 2000-07-28 2002-02-07 Lion Bioscience Ag Pharmacokinetic tool and method for predicting metabolism of a compound in a mammal
US7319945B1 (en) * 2000-11-10 2008-01-15 California Institute Of Technology Automated methods for simulating a biological network
US6937257B1 (en) * 2001-01-31 2005-08-30 Pharsight Corporation Unit tracking and notification in a graphical drug model editor
US7043415B1 (en) * 2001-01-31 2006-05-09 Pharsight Corporation Interactive graphical environment for drug model generation
US20020111850A1 (en) * 2001-02-12 2002-08-15 Chevron Oronite Company Llc System and method for new product clearance and development
US6631291B2 (en) * 2001-05-18 2003-10-07 Instrumentarium Corp. Closed loop drug administration method and apparatus using EEG complexity for control purposes
EP1417626A2 (en) * 2001-07-13 2004-05-12 Pharmacopeia, Inc. System and method for aqueous solubility prediction
DE10142019A1 (en) * 2001-08-28 2003-03-20 Philips Corp Intellectual Pty Circuit arrangement for demodulating signals
CA2496143A1 (en) * 2001-10-12 2003-04-17 University Of Utah Research Foundation Anesthesia drug monitor
US7027970B2 (en) * 2001-10-19 2006-04-11 Globomax Llc Tool for in vitro-in vivo correlation
US20030078760A1 (en) * 2001-10-19 2003-04-24 Globomax Holdings, Llc Population pharmacokinetic modeling and analysis (PDx-POP™)
US7415359B2 (en) * 2001-11-02 2008-08-19 Gene Network Sciences, Inc. Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
US6799123B2 (en) * 2001-11-05 2004-09-28 Lyn Hughes Dissolution test equipment and method
DE10160270A1 (en) * 2001-12-07 2003-06-26 Bayer Ag Computer system and method for calculating ADME properties
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
WO2003104439A2 (en) * 2002-03-12 2003-12-18 Surface Logix, Inc. Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound
US7590517B2 (en) * 2002-05-28 2009-09-15 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
AU2003250701A1 (en) * 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
WO2004025393A2 (en) * 2002-09-16 2004-03-25 Optimata, Ltd. An interactive technique for optimizing drug development from the pre-clinical phases through phase-iv
ATE380810T1 (en) * 2002-10-09 2007-12-15 Critical Outcome Technologies PROTEIN TYROSINE KINASE INHIBITORS
US9740817B1 (en) 2002-10-18 2017-08-22 Dennis Sunga Fernandez Apparatus for biological sensing and alerting of pharmaco-genomic mutation
DE10256315A1 (en) 2002-12-03 2004-06-17 Bayer Ag Computer system and method for calculating a pharmacokinetic behavior of a chemical substance in insects
WO2004065616A2 (en) 2003-01-16 2004-08-05 The General Hospital Corporation Use of three-dimensional microfabricated tissue engineered systems for pharmacologic applications
WO2004075075A1 (en) * 2003-01-21 2004-09-02 Alza Corporation A computational model for transdermal drug delivery
US7960166B2 (en) 2003-05-21 2011-06-14 The General Hospital Corporation Microfabricated compositions and processes for engineering tissues containing multiple cell types
US7853406B2 (en) * 2003-06-13 2010-12-14 Entelos, Inc. Predictive toxicology for biological systems
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
US8346482B2 (en) * 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
DE10345836A1 (en) * 2003-10-02 2005-04-21 Bayer Technology Services Gmbh Method for simulating the interaction of chemical substances with living organisms
JP4247101B2 (en) * 2003-12-10 2009-04-02 株式会社東芝 Design support system
JP2005245667A (en) * 2004-03-03 2005-09-15 Koninkl Philips Electronics Nv Medicine administration design system
US20070165926A1 (en) * 2004-05-10 2007-07-19 Koninklijke Philips Electronics, N.V. Data processing system for compartmental analysis
DE102004025534A1 (en) * 2004-05-25 2005-12-15 Bayer Technology Services Gmbh Method for (two-stage) dose and dosage finding
EP1754176A2 (en) * 2004-05-28 2007-02-21 Philips Intellectual Property & Standards GmbH System for the evaluation of tracer concentration in a reference tissue and a target region
JP2008502377A (en) * 2004-05-28 2008-01-31 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Noninvasive measurement system for blood tracer concentration
US20050278124A1 (en) * 2004-06-14 2005-12-15 Duffy Nigel P Methods for molecular property modeling using virtual data
US20060052943A1 (en) * 2004-07-28 2006-03-09 Karthik Ramani Architectures, queries, data stores, and interfaces for proteins and drug molecules
US8396670B2 (en) * 2004-08-16 2013-03-12 Venture Milling, Inc. Process, system and method for improving the determination of digestive effects upon an ingestable substance
WO2006060214A2 (en) * 2004-11-18 2006-06-08 The Regents Of The University Of California Apparatus and methods for manipulation and optimization of biological systems
HUE034171T2 (en) 2004-11-24 2018-02-28 Bayer Healthcare Llc Devices, systems and methods for fluid delivery
EP1839191A4 (en) * 2004-12-16 2008-01-23 Entelos Inc Methods and models for cholesterol metabolism
DE112006000937T5 (en) * 2005-04-15 2008-08-28 Thermo Crs Ltd., Burlington Method and system for testing samples
WO2006119325A2 (en) * 2005-05-02 2006-11-09 Plectix Biosystems, Inc. Using biological models
US7331251B2 (en) * 2005-06-22 2008-02-19 Idaho State University Dissolution testing of solid dosage forms intended to be administered in the oral cavity
EP1929282A4 (en) * 2005-08-31 2009-06-03 Affymax Inc Derivatization and low level detection of drugs in biological fluid and other solution matrices using a proxy marker
CA2628108C (en) 2005-11-10 2020-01-07 In Silico Biosciences, Inc. Method and apparatus for computer modeling the human brain for predicting drug effects
DE102005061270A1 (en) * 2005-12-20 2007-06-28 Universität Hamburg Procedure for structure-based virtual screening of biologically active compounds, comprises categorizing and/or sorting the compounds in catalogue on the basis of their physicochemical and/or geometrical and/or structural characteristics
EP1884878A1 (en) * 2006-08-02 2008-02-06 Hitachi Ltd. Computer system for simulating a physical system
WO2008046045A1 (en) * 2006-10-12 2008-04-17 Cylene Pharmaceuticals, Inc. Drug biovailability screens
KR100856517B1 (en) 2007-01-03 2008-09-04 주식회사 인실리코텍 System, method and program for tissue target prediction of peptide sequence by mathematical model
DK2097835T3 (en) 2006-12-29 2018-09-03 Bayer Healthcare Llc PATIENT-BASED PARAMETER GENERATION SYSTEMS FOR MEDICAL INJECTION PROCEDURES
WO2008083491A1 (en) 2007-01-11 2008-07-17 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
WO2008120105A2 (en) * 2007-03-30 2008-10-09 9898 Limited Pharmaceutical platform technology for the development of natural products
US8718944B2 (en) * 2007-05-22 2014-05-06 Worcester Polytechnic Institute Patient-specific image-based computational modeling and techniques for human heart surgery optimization
US20090037539A1 (en) * 2007-08-02 2009-02-05 Telefonaktiebolaget Lm Ericsson (Publ) Methods and Systems for Message Interworking
US8738116B2 (en) * 2007-09-21 2014-05-27 National Research Council Of Canada Method and apparatus for periodontal diagnosis
US8466151B2 (en) * 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
WO2009086550A1 (en) * 2008-01-03 2009-07-09 Abbott Laboratories Predicting long-term efficacy of a compound in the treatment of psoriasis
CA2758393A1 (en) * 2008-04-18 2009-10-22 The University Of Manchester Imaging technique
US20090271375A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination treatment selection methods and systems
US20090271347A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring bioactive agent use
US20100063368A1 (en) * 2008-04-24 2010-03-11 Searete Llc, A Limited Liability Corporation Computational system and method for memory modification
US20090270687A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for modifying bioactive agent use
US9282927B2 (en) 2008-04-24 2016-03-15 Invention Science Fund I, Llc Methods and systems for modifying bioactive agent use
US20090271009A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination treatment modification methods and systems
US9560967B2 (en) * 2008-04-24 2017-02-07 The Invention Science Fund I Llc Systems and apparatus for measuring a bioactive agent effect
US20090270688A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting a combination treatment
US7974787B2 (en) * 2008-04-24 2011-07-05 The Invention Science Fund I, Llc Combination treatment alteration methods and systems
US9026369B2 (en) 2008-04-24 2015-05-05 The Invention Science Fund I, Llc Methods and systems for presenting a combination treatment
US9064036B2 (en) * 2008-04-24 2015-06-23 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
US20100017001A1 (en) * 2008-04-24 2010-01-21 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US9239906B2 (en) * 2008-04-24 2016-01-19 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US20090270694A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US20100041958A1 (en) * 2008-04-24 2010-02-18 Searete Llc Computational system and method for memory modification
US20100076249A1 (en) * 2008-04-24 2010-03-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20090312668A1 (en) * 2008-04-24 2009-12-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US9649469B2 (en) * 2008-04-24 2017-05-16 The Invention Science Fund I Llc Methods and systems for presenting a combination treatment
US20100100036A1 (en) * 2008-04-24 2010-04-22 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational System and Method for Memory Modification
US8682687B2 (en) 2008-04-24 2014-03-25 The Invention Science Fund I, Llc Methods and systems for presenting a combination treatment
US20100280332A1 (en) * 2008-04-24 2010-11-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring bioactive agent use
US20100004762A1 (en) * 2008-04-24 2010-01-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100030089A1 (en) * 2008-04-24 2010-02-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US8615407B2 (en) 2008-04-24 2013-12-24 The Invention Science Fund I, Llc Methods and systems for detecting a bioactive agent effect
US9662391B2 (en) * 2008-04-24 2017-05-30 The Invention Science Fund I Llc Side effect ameliorating combination therapeutic products and systems
US20100081860A1 (en) * 2008-04-24 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational System and Method for Memory Modification
US20100130811A1 (en) * 2008-04-24 2010-05-27 Searete Llc Computational system and method for memory modification
US20100081861A1 (en) * 2008-04-24 2010-04-01 Searete Llc Computational System and Method for Memory Modification
US20100069724A1 (en) * 2008-04-24 2010-03-18 Searete Llc Computational system and method for memory modification
US20100042578A1 (en) * 2008-04-24 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100041964A1 (en) * 2008-04-24 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US9449150B2 (en) 2008-04-24 2016-09-20 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US20100015583A1 (en) * 2008-04-24 2010-01-21 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational System and method for memory modification
US20100125561A1 (en) * 2008-04-24 2010-05-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100022820A1 (en) * 2008-04-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US8876688B2 (en) * 2008-04-24 2014-11-04 The Invention Science Fund I, Llc Combination treatment modification methods and systems
US7801686B2 (en) * 2008-04-24 2010-09-21 The Invention Science Fund I, Llc Combination treatment alteration methods and systems
US8606592B2 (en) 2008-04-24 2013-12-10 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
US20090269329A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination Therapeutic products and systems
US20090271122A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US8930208B2 (en) 2008-04-24 2015-01-06 The Invention Science Fund I, Llc Methods and systems for detecting a bioactive agent effect
KR100946145B1 (en) * 2008-05-13 2010-03-08 성균관대학교산학협력단 A Sequence Similarity Measuring Apparatus and Control Method thereof
CA2999321A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8321148B2 (en) * 2008-10-24 2012-11-27 Amicus Therapeutics, Inc. Multiple compartment dosing model
US20100166613A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163036A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163027A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100169259A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163025A1 (en) * 2008-12-30 2010-07-01 Searete Llc Methods and systems for presenting an inhalation experience
US20100168525A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163038A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163034A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163024A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Methods and systems for presenting an inhalation experience
US20100168529A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163033A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100169260A1 (en) * 2008-12-30 2010-07-01 Searete Llc Methods and systems for presenting an inhalation experience
US8694330B2 (en) * 2008-12-30 2014-04-08 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US8706518B2 (en) * 2008-12-30 2014-04-22 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US8738395B2 (en) * 2008-12-30 2014-05-27 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US20100168602A1 (en) * 2008-12-30 2010-07-01 Searete Llc Methods and systems for presenting an inhalation experience
US8725529B2 (en) * 2008-12-30 2014-05-13 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US8712794B2 (en) * 2008-12-30 2014-04-29 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US8738345B2 (en) 2009-05-29 2014-05-27 Carl A. Wesolowski Method for evaluating renal function
NZ599873A (en) 2009-10-19 2014-09-26 Theranos Inc Integrated health data capture and analysis system
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
KR101298303B1 (en) * 2010-04-27 2013-08-20 울산대학교 산학협력단 COMBINATION ANALYSIS SYSTEM FOR Pharmacokinetic AND Pharmacodynamic MODELING OF DRUG
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
RU2016138172A (en) * 2010-06-24 2018-12-12 Байер Медикэл Кер Инк. MODELING THE DISTRIBUTION OF A PHARMACEUTICAL PRODUCT AND GENERATION OF PARAMETERS FOR INJECTION PROTOCOLS
US9367812B2 (en) * 2010-08-25 2016-06-14 Optibrium Ltd. Compound selection in drug discovery
DE102010060311B3 (en) * 2010-11-02 2012-02-02 Freie Universität Berlin Method for supporting planning, implementation and analysis of clinical studies for e.g. pharmacological data of patient, involves computing value of measurable parameter based on variable that is characteristic for combined compartments
US9245336B2 (en) 2010-12-15 2016-01-26 Koninklijke Philips N.V. Contour guided deformable image registration
CN103077296B (en) * 2011-10-25 2015-11-18 复旦大学附属华山医院 Based on the in-vitro simulated method of the intravenous injection pharmacokinetic model of velocity of flow adjust
DE102011085180A1 (en) * 2011-10-25 2013-04-25 Piramal Imaging Sa Method for generating optimized tomography images
CN102682209B (en) * 2012-05-03 2014-11-05 桂林理工大学 Variable selection method for modeling organic pollutant quantitative structure and activity relationship
RU2605272C2 (en) 2012-05-14 2016-12-20 БАЙЕР ХелсКер ЛЛСи Systems and methods of determining protocols of injection of pharmaceutical fluid on the basis of voltage on x-ray tube
EP2880600A2 (en) * 2012-08-02 2015-06-10 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method and computing system for modelling a primate brain
US20160335412A1 (en) * 2013-01-30 2016-11-17 Geoffrey Tucker Systems and methods for predicting and adjusting the dosage of medicines in individual patients
US20150147738A1 (en) * 2013-03-13 2015-05-28 Bowling Green State University Methods and systems for teaching biological pathways
WO2015017798A2 (en) 2013-08-02 2015-02-05 CRIXlabs, Inc. Method and system for predicting spatial and temporal distributions of therapeutic substance carriers
EP2911075A1 (en) * 2014-02-25 2015-08-26 LTS LOHMANN Therapie-Systeme AG System for determining a suitability of an agent for transdermal or transmucosal application and corresponding method
TW201618795A (en) * 2014-04-15 2016-06-01 波泰里斯股份有限公司 Systems and methods to improve organ function and organ transplant longevity
ES2860423T3 (en) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Methods and Systems for Converting Stem Cells to Gastric Tissues by Targeted Differentiation
AU2015331848B2 (en) 2014-10-17 2022-03-03 Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
EP3261008B1 (en) 2015-02-17 2021-09-08 Cipherome, Inc. Method for selecting anticancer agent based on protein damage information of individual to prevent anticancer agent side effects
CA2976320C (en) * 2015-07-29 2019-02-19 Synaptive Medical (Barbados) Inc. Method, system and apparatus for adjusting image data to compensate for modality-induced distortion
SG11201808475XA (en) 2016-04-15 2018-10-30 Baxalta Inc Method and apparatus for providing a pharmacokinetic drug dosing regiment
CA3016641A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
EP3478159B1 (en) 2016-06-30 2022-04-13 Given Imaging Ltd. Assessment and monitoring of a mucosal disease in a subject's gastrointestinal tract
US11767515B2 (en) 2016-12-05 2023-09-26 Children's Hospital Medical Center Colonic organoids and methods of making and using same
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
US10854326B2 (en) * 2017-11-21 2020-12-01 Verisim Life Inc. Systems and methods for full body circulation and drug concentration prediction
US11468973B2 (en) * 2018-02-02 2022-10-11 Richard Postrel Leveraging genomic, phenotypic and pharmacological data to cure disease
WO2020009916A1 (en) * 2018-07-03 2020-01-09 Yale University System and method for using microbiome to de-risk drug development
US11580275B1 (en) * 2018-12-18 2023-02-14 X Development Llc Experimental discovery processes
EP3683800A1 (en) * 2019-01-18 2020-07-22 Tata Consultancy Services Limited Method and system for insilico design and testing of formulations using physiochemical skin model
US20210050108A1 (en) * 2019-07-19 2021-02-18 Tata Consultancy Services Limited Systems and methods for generating optimized set of pharmacokinetic (pk) and pharmacodynamic (pd) parameters
CN110766084B (en) * 2019-10-28 2021-06-15 北京理工大学 Small sample SAR target identification method based on CAE and HL-CNN
JP7302621B2 (en) * 2021-04-02 2023-07-04 株式会社豊田中央研究所 Organic material transport property evaluation device and organic material transport property evaluation method
WO2022244022A1 (en) * 2021-05-21 2022-11-24 Aizen Algo Private Limited Method and system for prediction of time points in pharmacokinetic studies
WO2022248703A2 (en) 2021-05-27 2022-12-01 Cyprus University Of Technology Physiologically based toxicokinetic (pbtk) modeling for implant toxicology

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019359A1 (en) * 1994-01-12 1995-07-20 Massachusetts Institute Of Technology Process for making xanthene or cubane based compounds, and protease inhibitors
US5770384A (en) * 1994-12-22 1998-06-23 New England Medical Center Hospitals, Inc Method for determining compound interaction with E2 binding proteins
US5789160A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Parallel selex

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335438A (en) 1980-04-17 1982-06-15 Smolen Victor F Method and apparatus for automatic dissolution testing of products
US4411989A (en) 1981-08-13 1983-10-25 Midwest Research Institute Processes and devices for detection of substances such as enzyme inhibitors
GB2206429A (en) 1987-07-02 1989-01-05 Infrared Eng System determining properties or identity of a sample
US4775794A (en) 1987-11-02 1988-10-04 Zenon Environmental Inc. Process and apparatus for measurement of light-absorbable components dissolved in liquids
US4975581A (en) 1989-06-21 1990-12-04 University Of New Mexico Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids
US5680590A (en) 1990-09-21 1997-10-21 Parti; Michael Simulation system and method of using same
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
US5326778A (en) 1992-03-03 1994-07-05 Research Corporation Technologies, Inc. Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy
US5956501A (en) 1997-01-10 1999-09-21 Health Hero Network, Inc. Disease simulation system and method
WO1994023705A1 (en) 1993-04-20 1994-10-27 Tsrl, Inc. Multi-stage drug delivery system
US5703792A (en) 1993-05-21 1997-12-30 Arris Pharmaceutical Corporation Three dimensional measurement of molecular diversity
US5569452A (en) 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
ATE272719T1 (en) 1993-11-26 2004-08-15 Lawrence B Hendry THE DESIGN OF DRUGS THAT INTERVENTION IN RECEPTOR-LIGAND-DNA INTERACTIONS
US5625579A (en) 1994-05-10 1997-04-29 International Business Machines Corporation Stochastic simulation method for processes containing equilibrium steps
AU2788695A (en) 1994-10-28 1996-05-23 Neurosearch A/S Patch clamp apparatus and technique having high throughput and low fluid volume requirements
US5914891A (en) 1995-01-20 1999-06-22 Board Of Trustees, The Leland Stanford Junior University System and method for simulating operation of biochemical systems
US5699268A (en) 1995-03-24 1997-12-16 University Of Guelph Computational method for designing chemical structures having common functional characteristics
US5657255C1 (en) 1995-04-14 2002-06-11 Interleukin Genetics Inc Hierarchic biological modelling system and method
WO1997016717A1 (en) 1995-11-03 1997-05-09 Eli Lilly And Company Automated permeability analysis system
DE865502T1 (en) 1995-12-07 1999-08-19 Scriptgen Pharm Inc FLUORESCENT-BASED DETECTION METHOD FOR LIGANDS
US5783397A (en) 1995-12-11 1998-07-21 Northeastern University Screening natural samples for new therapeutic compounds using capillary electrophoresis
AU1540997A (en) 1996-02-09 1997-08-28 Phytera Symbion Aps Balanol analogues
US5880972A (en) 1996-02-26 1999-03-09 Pharmacopeia, Inc. Method and apparatus for generating and representing combinatorial chemistry libraries
US6235520B1 (en) 1996-06-27 2001-05-22 Cellstat Technologies, Inc. High-throughput screening method and apparatus
WO1998000231A1 (en) 1996-06-28 1998-01-08 Caliper Technologies Corporation High-throughput screening assay systems in microscale fluidic devices
EP0818744A3 (en) 1996-07-08 1998-07-08 Proteus Molecular Design Limited Process for selecting candidate drug compounds
AU4330997A (en) 1996-08-29 1998-03-19 Chiron Corporation Method for analysing absorption, distribution, metabolism, excretion (ADME) an d pharmacokinetics properties of compound mixtures
US5854992A (en) 1996-09-26 1998-12-29 President And Fellows Of Harvard College System and method for structure-based drug design that includes accurate prediction of binding free energy
ATE287402T1 (en) 1997-02-04 2005-02-15 Univ California NANOMOLAR, NON-PEPTIDIC INHIBITORS OF CATHEPSIN D
EP0918296A1 (en) 1997-11-04 1999-05-26 Cerep Method of virtual retrieval of analogs of lead compounds by constituting potential libraries

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789160A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Parallel selex
WO1995019359A1 (en) * 1994-01-12 1995-07-20 Massachusetts Institute Of Technology Process for making xanthene or cubane based compounds, and protease inhibitors
US5770384A (en) * 1994-12-22 1998-06-23 New England Medical Center Hospitals, Inc Method for determining compound interaction with E2 binding proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE DERWENT ON WEST CARELL ET AL.: "Biologically active molecule combinatorial library production - by reacting core molecule with tool molecules, especially for preparation of new xanthene derivative serine protease inhibitors", XP002932988 *
DATABASE DIALOG HOLFORD N.H.G.: "Drugmodel (pharmacokinetic modelling)" *
GEX-FABRY ET AL.: "pharmacokenetics of drugs", 1994, SPRINGER-VERLAG, BERLIN, XP002932986 *
HARVEY S.C.: "Remington's pharmaceutical sciences", 1990, MACK PUBLISHING CO., EASTON, PENNSYLVANIA, XP002932987 *
PROCEEDINGS OF THE FIFTH ANNUAL SYMPOSIUM ON COMPUTER APPLICATIONS IN MEDICINAL CARE, IEEE, 1981, NEW YORK, pages 603 - 606 *

Also Published As

Publication number Publication date
AU767944B2 (en) 2003-11-27
DE69930137D1 (en) 2006-04-27
CA2344036A1 (en) 2000-03-23
US6542858B1 (en) 2003-04-01
WO2000015178A2 (en) 2000-03-23
EP1185948A4 (en) 2002-06-26
AU6247499A (en) 2000-04-03
EP1144675A4 (en) 2007-05-02
EP1185948A1 (en) 2002-03-13
US20010041964A1 (en) 2001-11-15
JP2003521673A (en) 2003-07-15
JP2002524809A (en) 2002-08-06
AU768368B2 (en) 2003-12-11
WO2000015178A9 (en) 2001-10-04
EP1185948B1 (en) 2006-03-01
US6996473B2 (en) 2006-02-07
US20020061540A1 (en) 2002-05-23
ATE319136T1 (en) 2006-03-15
US20020035459A1 (en) 2002-03-21
CA2343914A1 (en) 2000-03-23
WO2000016231A1 (en) 2000-03-23
US20020010550A1 (en) 2002-01-24
AU6145199A (en) 2000-04-03
US6647358B2 (en) 2003-11-11
US20020013662A1 (en) 2002-01-31
EP1144675A2 (en) 2001-10-17

Similar Documents

Publication Publication Date Title
WO2000015178A3 (en) Computer implemented pharmacokinetics method and program
BRPI0409962A (en) particulate co-formulation of an active substance and an excipient, pharmaceutical or nutritional composition, pharmaceutical or nutritional product, method for preparing a particulate co-formulation of an active substance and an excipient, and use of an active substance and an excipient
NZ505914A (en) Three-dimensional structures and models of fc receptors and uses thereof
DE69518334T2 (en) PHARMACEUTICAL AEROSOL WHICH CONTAINS AT LEAST ONE SUGAR
AR023939A1 (en) COMPUTERS DERIVED FROM PIPERIDINE USEFUL AS AN ANTHOGONIST OF CCR5, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THE USE OF THE SAME ONLY OR IN COMBINATION WITH ANOTHER ANTIVIRAL AGENT FOR THE PREPARATION OF A MEDICINAL PRODUCT AND A KIT
BR9915095A (en) Pharmaceutical composition administered in aerosol
GEP20022839B (en) 2-(Purin-9-Yl)-Tetrahydrofuran-3,4-Diol Derivatives
GEP20063985B (en) Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
BR0213761A (en) Compositions, pharmaceutical preparation, industrialized article, mammalian treatment method, host cell, method for producing a glycoprotein and use of the composition
PL336885A1 (en) Therapeutic products in the aerosol form
EP1908463A3 (en) Methods of inducing ovulation using a non-polypeptide camp level modulator
WO2002087567A3 (en) Polymethoxylated flavones for treating insulin resistance
BR0110837A (en) Combination Chemotherapy
BR0212857A (en) Formulations and use of these
BR0008713A (en) Processes for preparing oral pharmaceutical formulations and compositions with ecb
WO2004028476A3 (en) Artemisinin-derived trioxane dimers
Rao et al. Deuterated Drugs
Murry et al. Influence of phenytoin on the disposition of irinotecan: a case report
ATE234319T1 (en) GLYCOSYLATED GINKGOLIDE DERIVATIVES, THEIR USE AS MEDICINAL PRODUCTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
BRPI0515891A (en) method for producing a medical aerosol product and a medical aerosol product
Karl et al. Pharmacokinetics of oral triazolam in children
MY135460A (en) Method of stimulating hair growth using benzopyrans
Farber et al. Clinical studies of actinomycin D with special reference to Wilms’ tumor in children
Spector Effect of beta-adrenergic agents on skin test responses and bronchial challenge responses
AP2004003082A0 (en) Pharmaceutical combinations of adenosine A-2A and beta-2- adrenergic receptor agonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2344036

Country of ref document: CA

Ref country code: CA

Ref document number: 2344036

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 569763

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 62474/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999949642

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 09786361

Country of ref document: US

AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 114-126, DESCRIPTION, REPLACED BY NEW PAGES 114-129; PAGES 127-170, CLAIMS, REPLACED BY NEW PAGES 130-173; PAGES 1/35-35/35, DRAWINGS, REPLACED BY NEW PAGES 1/38-38/38; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 1999949642

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 62474/99

Country of ref document: AU